Skip to main content Skip to office menu Skip to footer
Minnesota Legislature

Office of the Revisor of Statutes

SF 2368

as introduced - 90th Legislature (2017 - 2018) Posted on 07/30/2018 03:14pm

KEY: stricken = removed, old language.
underscored = added, new language.

Current Version - as introduced

Line numbers 1.1 1.2 1.3 1.4 1.5
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15
2.16 2.17 2.18 2.19
2.20 2.21 2.22 2.23

A bill for an act
relating to health; establishing a biomedicine and bioethics innovation grant
program; appropriating money; proposing coding for new law in Minnesota
Statutes, chapter 144.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

new text begin [144.88] MINNESOTA BIOMEDICINE AND BIOETHICS INNOVATION
GRANTS.
new text end

new text begin Subdivision 1. new text end

new text begin Account established. new text end

new text begin A Minnesota biomedicine and bioethics innovation
account is established in the special revenue fund. Money in the account shall be used for
grants awarded according to subdivision 2.
new text end

new text begin Subd. 2. new text end

new text begin Grants. new text end

new text begin (a) The commissioner of health, in consultation with interested parties
with relevant knowledge and expertise as specified in subdivision 3, shall award grants from
the Minnesota biomedicine and bioethics innovation account to entities that apply for a
grant under this subdivision. Grant funds must be used to fund biomedical and bioethical
research and related clinical translation and commercialization activities in this state. Entities
applying for a grant must do so in a form and manner specified by the commissioner. The
commissioner and interested parties shall use the following criteria to award grants under
this subdivision:
new text end

new text begin (1) the likelihood that the research will lead to a new discovery;
new text end

new text begin (2) the prospects for commercialization of the research;
new text end

new text begin (3) the likelihood that the research will strengthen Minnesota's economy through the
creation of new businesses, increased public or private funding for research in Minnesota,
or attracting additional clinicians and researchers to Minnesota; and
new text end

new text begin (4) whether the proposed research includes a bioethics research plan to ensure the research
is conducted using ethical research practices.
new text end

new text begin (b) Projects that include the acquisition or use of human fetal tissue are not eligible for
grants under this subdivision. For purposes of this paragraph, "human fetal tissue" has the
meaning given in United States Code, title 42, section 289g-1(f).
new text end

new text begin Subd. 3. new text end

new text begin Consultation. new text end

new text begin In awarding grants under subdivision 2, the commissioner must
consult with interested parties who are able to provide the commissioner with technical
information, advice, and recommendations on grant projects and awards. Interested parties
with whom the commissioner must consult include but are not limited to representatives of
the University of Minnesota, Mayo Clinic, and private industries who have expertise in
biomedical research, bioethical research, clinical translation, commercialization, and medical
venture financing.
new text end

Sec. 2. new text beginTRANSFER.
new text end

new text begin $5,000,000 in fiscal year 2018 is transferred from the general fund to the Minnesota
biomedicine and bioethics innovation account in the special revenue fund. This is a onetime
transfer.
new text end

Sec. 3. new text beginAPPROPRIATION.
new text end

new text begin $....... in fiscal year 2018 and $....... in fiscal year 2019 are appropriated from the
Minnesota biomedicine and bioethics innovation account in the special revenue fund to the
commissioner of health for grants under Minnesota Statutes, section 144.88.
new text end